Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration

摘要

Within the pharmaceutical and biotech industries, therapeutic monoclonal antibodies (mAbs) have attracted significant attention during the last few decades. Their use as therapeutics is steadily increasing, with currently 31 therapeutic mAbs approved worldwide for treatment of a wide range of diseases, including cancer and autoimmune-disorders. Currently approved mAbs are generally administered through intravenous injection (IV). This requires professional healthcare assistance or hospitalisation. Many of the treated diseases are chronic and require frequent administration; subcutaneous (SC) administration is thus highly preferable, as this would enable patient self-administration. However, mAb treatment requires relatively large doses, often in the range of several mg/kg bodyweight. The volume restrictions (< 1.5 ml) for SC injections, therefore, necessitate the development of high concentration formulations [1].